In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 31, Issue 1, 2000, Pages 118-122

  Petmitr, Porntip Chavalitshewinkoon ^a   Ramdja, Muhaimin ^a   Kajorndechakiat, Somsri ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTIINFECTIVE AGENT; ANTITRICHOMONAL AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ELLIPTICINE; ELLIPTICINE DERIVATIVE; ENZYME INHIBITOR; METRONIDAZOLE; QUINOLONE DERIVATIVE;

ANIMAL; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SENSITIVITY; ENZYMOLOGY; TRICHOMONAS VAGINALIS;

AMSACRINE; ANIMALS; ANTI-INFECTIVE AGENTS; ANTITRICHOMONAL AGENTS; DNA TOPOISOMERASES, TYPE II; ELLIPTICINES; ENZYME INHIBITORS; FLUOROQUINOLONES; METRONIDAZOLE; PARASITIC SENSITIVITY TESTS; TRICHOMONAS VAGINALIS;

EID: 0034156781     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brabin L, Kemp J, Obunge OK, et al. Reproductive tract infections and abortions among adolescents girl in rural Nigeria. Lancet 1995; 345: 300-4.
2. Cameron DW, Padian NS. Sexual transmission of HIV and the epidemiology of other sexually transmitted diseases. AIDS 1990; 4 (suppl 1): 99-103.
3. Chavalitshewinkoon P, Wilairat P, Gamage S, Denny W, Figgit D, Ralph R. Strucuture-activity relationship and mode of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro. Antimicrob Agents Chemother 1993; 37: 403-6.
4. Cosar C, Julou L Activity of 1-(2′-hydroxyethyl)-2-methyl-5-nitroimidazole (8823 RP) against experimental Trichomonas vaginalis infection. Ann Inst Pasteur 1959; 96: 238-41.
5. Diamond LS. The establishment of various trichomonads of animals and man in axenic cultures. J Parasitol 1957; 43: 488-90.
6. Drlica K. Biology of bacterial deoxyribonucleic acid topoisomerases. Microbiol Rev 1984; 48: 273-89.
7. Fouts AC, Kraus SJ. Trichomonas vaginalis: reevaluation of its clinical presentation and laboratory diagnosis. J Infect Dis 1980; 141: 137-43.
8. Furlong NB, Sato J, Brown T, Chavez F, Hubert RB. Induction of limited DNA damaged by the antitumor agents Cain's acridine. Cancer Res 1978; 38: 1329-35.
9. Gram I, Macaluso M, Churchill J, Stalsberg H. Trichomonas vaginalis (TV) and human papillomavirus (HPV) infection and the incidence of cervical intraepithelial neoplasia (CIN) grade III. Cancer Causes Control 1992; 3: 231-6.
10. Grodstein F, Goldman MB, Cramer DW. Relation of tubal infertility to a history of sexually transmitted diseases. Am J Epidemiol 1993; 137: 577-84.
11. Hardy PH, Hardy JB, Nell EE, Graham DA, Spence MR, Rosenbaum RC. Prevalence of six sexually transmitted disease agents among pregnant inner-city adolescents and pregnancy outcome. Lancet 1984; ii: 333-7.
12. Heine P, McGregor JA. Trichomonas vaginalis: a reemerging pathogen. Clin Obstet Gynecol 1993; 36: 137-44.
13. Hollander DH. Colonial morphology of Trichomonas vaginalis in agar. J Parasitol 1976; 62: 826-8.
14. Johnson PJ. Metronidazole and drug resistance. Parasitol Today 1993; 9: 183-6.
15. Johnson PJ, Lahti CJ, Bradley PJ. Biogenesis of the hydrogenosome in the anaerobic protist Trichomonas vaginalis. J Parasitol 1993; 79: 64-7.
16. Kharsany AB, Hosen AA, Moodley J, Bagaratee J, Gouws E. The association between sexually transmitted pathogenes and cervical intra-epithelial neoplasia in developing community. Genitourin Med 1993; 69: 357-60.
17. Laga M, Alary M, Nzila N, et al. Condom promotion, sexually transmitted disease treatment, and declining incidence of HIV-1 infection in female Zairian sex workers. Lancet 1994; 344: 246-8.
18. Liu LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989; 58: 351-75.
19. Lossick JG. Treatment of Trichomonas vaginalis infections. Rev Infect Dis 1982; 4: 801-18.
20. Lossick JG. Chemotherapy of nitroimidazole resistant vaginal trichomoniasis. Acta Univ Carol Biol 1986; 30: 533-45.
21. Pommier Y. DNA topoisomerase I and II in cancer chemotherapy: update and perspective. Cancer Chem other Pharmacol 1993; 32: 103-8.
22. Minkoff H, Grunebaum AN, Schwarz RH, et al. Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. Am J Obstet Gynecol 1984; 150: 965-72.
23. Muller M. The hydrogenosome. Symp Soc Gen Microbiol 1980; 30: 127-42.
24. Muller M. Mode of action of metronidazole on aerobic bacteria and protozoa. Surgery 1983; 93: 165.
25. Muller M. Energy metabolism of protozoa without mitochondria. Ann Rev Microbiol 1988; 42: 465-88.
26. Nelson EM, Tewey KM, Liu LF. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino) methanesulfon-m-aniside. Proc Natl Acad Sci USA 1984; 81: 1361-5.
27. Osheroff N. Biochemical basis for the interaction of type I and type II topoisomerase with DNA. Pharmacol Ther 1989; 41: 223-41.
28. Ralph RK. On the mechanism of action of 4′-(9-acridinylamino) methanesulfon-m-aniside. Eur J Cancer 1980; 16: 585-600.
29. Tachezy J, Kulda J, Tomkova E. Aerobic resistance of Trichomonas vaginalis to metronidazole induced in vitro. Parasitology 1993; 106: 31-7.
30. Wang AL, Wang CC. Isolation and characterization of DNA from Trichomonas foetus and Trichomonas vaginalis. Mol Biochem Parasitol 1985; 14: 323-35.
31. Wilson WR, Baguley BC, Wabelin LPG, Waring MJ. Interaction of the antitumor drug 4′-(9-acridinylamino) methasulfon-m-aniside and related acridines with nucleic acids. J Mol Pharmacol 1981; 20: 404-14.
32. Wolhner-Hanssen P, Krieger JN, Stevens CE. Clinical manifestations of vaginal trichomoniasis. JAMA 1989; 261: 571-6.
33. World Health Organization. An over of selected curable sexually transmitted diesease. In: Global program on AIDS. Geneva: World Health Organization, 1995.
34. Zhang ZF, Begg CB. Is Trichomonas vaginalis a cause of cervical neoplasma? Result from a combined analysis of 24 studies. Int J Epidemiol 1994; 23: 682-90.